Compare Ford Motor Company (F) vs Moderna, Inc. (MRNA) Price & Performance

Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.

The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.

Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.

While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.